Should blood donors be routinely screened for irregular antibodies?

Immunohematology

Volumn 28, Issue 2, 2012, Pages 60-66

  Garcia M A ^a   Bautista, L ^b   Palomino, F ^c  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

^b Clinica Lorencita Villegas   (Colombia)

^c National Society of the Colombian Red Cross   (Colombia)

Author keywords

Alloantibody identification; Alloantibody screening; Blood bank; Blood donor; Blood recipient

Indexed keywords

ALLOANTIBODY; ANTIBODY;

ADULT; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD ANALYSIS; BLOOD BANK; BLOOD COMPONENT; BLOOD DONOR; BLOOD GROUP RHESUS SYSTEM; BLOOD TRANSFUSION; CLINICAL ARTICLE; COLOMBIA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; SCREENING; BLOOD;

BLOOD DONORS; HUMANS; ISOANTIBODIES;

EID: 84891638193     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Mincheff MS, Meryman HT, Kapoor V, Alsop P, Wözel M. Blood transfusion and immunomodulation: a possible mechanism. Vox Sang 1993;65:18-24.
2. Mincheff MS, Meryman HT. Blood transfusion, blood storage and immunomodulation. Immunol Invest 1995;24:303-9.
3. Zimrin AB, Hess JR. Current issues relating to the transfusion of stored red blood cells. Vox Sang 2009;96:93-103.
4. Heal JM, Phipps RP, Blumberg N. One big unhappy family: transfusion alloimmunization, thrombosis, and immune modulation/inflammation. Transfusion 2009;49:1032-6.
5. Flegel WA. Immunogenicity reloaded. Blood 2009;114: 3979-80.
6. Tormey CA, Stack G. The characterization and classification of concurrent blood group antibodies. Transfusion 2009;49: 2709-18.
7. Initial detection and identification of alloantibodies to red cell antigens. Chapter 19. In: Brecher ME, Leger RM, Linden JV, Roseff SD. Technical manual. 15th ed. Arlington, VA: American Association of Blood Banks, 2005:423-53.
8. Villalobos J, Wittingham M, Vargas C. Anticuerpos irregulares contra eritrocitos en donantes del Banco Nacional de Sangre. [Irregular antibodies against red blood cells in blood donors.] http://www.hemasferio.com/src/img_up/GCIAMT/24.pdf. Accessed on August 20, 2010.
9. Posser N. Prevalencia de Anticorpos Irregulares em Doadores de Sangue do Hemocentro Regional de Passo Fundo-RS. [Prevalence of irregular antibodies in blood donors at regional blood bank of Passo Fundo-RS.] Available at: http://www.ulbracarazinho.edu.br/novo/grades/tcc%202008%202%20biomedicina/Nat%E1lia%20Posser%20Trentin.pdf. Accessed August 20, 2010.
10. Decreto 1571 de 1993. Por el cual se reglamenta parcialmente el T?ulo IX de la Ley 09 de 1979, en cuanto a funcionamiento de establecimientos dedicados a la extracci?, procesamiento, conservaci? y transporte de sangre total o de sus hemoderivados, se crean la Red Nacional de Bancos de Sangre y el Consejo Nacional de Bancos de Sangre y se dictan otras disposiciones sobre la materia. [Decree 1571 of 1993. Which regulates Title IX of Act 09 of 1979, in terms of operation of establishments engaged in the extraction, processing, preservation, and transportation of whole blood or its components, created the National Network of Blood Banks and National Council of Blood Banks and other provisions on the subject.] Available at: http://www.presidencia.gov.co/prensa_new/decretoslinea/1993/agosto/12/dec1571121993.pdf. Accessed January 13, 2010.
11. Resolución 901 1996. Manual de Normas Ténicas y Administrativas para Bancos de Sangre y Servicios de Transfusión Repúlica de Colombia. Available at: http://190.27.195.165/index.php?idcategoria=80695#. [Resolution 901 1996. Manual of Standard, administrative and procedures for Colombian Blood Banks (In Spanish)] https://www.icbf.gov.co/transparencia/derechobienestar/resolucion/resolucion_minsalud_r0901_96.html. Accessed July 09, 2012.
12. Dueñs VH, Cortes A, Rovetto P, Neuta PA. Embarazo y transfusión y su asociación con aloanticuerpos inesperados de significancia clíica contra antíenos eritrocitarios. [Pregnancy and transfusion and its association with clinically significant alloantibodies against unexpected red cell antigens.] Colombia Med 1999;30:26-31. Available in: http://www.google.com.co/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&sqi=2&ved=0CFIQFjAA&url=http%3A%2F%2Fcolombiamedica.univalle.edu.co%2Findex.php%2Fcomedica%2Farticle%2Fdownload%2F118%2F119&ei=P5f7T9eWPO620AGuiMTVBg&usg=AFQjCNHLLcvPMtwTGkst0lq4oyyYkMQtOg. Accessed July 09, 2012.
13. Galel SA, Nguyen DD, Fontaine MJ, Goodnough LT, Viele MK. Transfusion medicine. In: Greer JP, Foerster J, Rodgers GM, et al., eds. Wintrobe's clinical hematology. 12th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2009:490-527.
14. Sandoval C, De la Hoz A, Yunis E. Estructura genéica de la población Colombinana. [Genetic structure of the Colombian population.] Rev Fac Med Univ Nac Colomb 1993;41:3-14.
15. Beltrán M, Ayala M, Jara J. Frecuencia de grupos sanguíneos y factor Rh en donantes de Sangre, Colombia, 1996. [Frequency of blood groups and Rh factor in blood donors, Colombia, 1996.] Biomedica 1999;19:45-9.
16. Middelburg RA, van Stein D, Brië E, van der Bom JG. The role of donor antibodies in the pathogenesis of transfusionrelated acute lung injury: a systematic review. Transfusion 2008;48:2167-76.
17. Eder AF, Benjamin RJ. TRALI risk reduction: donor and component management strategies. J Clin Apher 2009;24: 122-9.
18. Koelewijn JM, Vrijkotte TG, van der Schoot CE, Bonsel GJ, de Haas M. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008;48:941-52.
19. Council of Europe. Guide to the preparation, use and quality assurance of blood components: recommendation No. R (95) 10th ed. Strasbourg: Council of Europe Publishing, 1997.
20. Takeshita A, Watanabe H, Fijihara H, et al. Collaborative study of irregular erythrocyte antibodies in Japan: results from the Japanese study group of allo-immunity and antigen diversity in Asian populations. Transfus Apher Sci 2010;43:3-8.
21. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002;42:37-43.
22. McAdams RM, Dotzler SA, Winter LW, Kerecman JD. Severe hemolytic disease of the newborn from anti-e. J Perinatol 2008;28:230-2.
23. Lee S, Zambas ED, Marsh WL, Redman CM. The human Kell blood group gene maps to chromosome 7q33 and its expression is restricted to erythroid cells. Blood 1993;81:2804-9.
24. Marsh WL, Oyen R, Alicea E, Linter M, Horton S. Autoimmune hemolytic anemia and the Kell blood groups. Am J Hematol 1979;7:155-62.
25. Vaughan JI, Manning M, Warwick RM, Letsky EA, Murray NA, Roberts IA. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 1998;338:798-803.
26. Hinchliffe RF, Nolan B, Vora AJ, Stamps R. Neonatal pure red cell aplasia due to anti-M. Arch Dis Child Fetal Neonatal Ed 2006;91:F467-8.
27. De Young-Owens A, Kennedy M, Rose RL, Boyle J, O'Shaughnessy R. Anti-M isoimmunization: management and outcome at the Ohio State University from 1969 to 1995. Obstet Gynecol 1997;90:962-6.
28. van Rhenen DJ, Vermeij J, de Voogt J, Bernes JC, Payrat JM. Quality and standardization in blood component preparation with an automated blood processing technique. Transfus Med 1998;8:319-24.
29. Barjas-Castro ML, Locatelli MF, Carvalho MA, Gilli SO, Castro V. Severe immune haemolysis in a group A recipient of a group O red blood cell unit. Transfus Med 2003;13:239-41.
30. Sigler E, Shvidel L, Yahalom V, Berrebi A, Shtalrid M. Clinical significance of serologic markers related to red blood cell autoantibodies production after red blood cell transfusionsevere autoimmune hemolytic anemia occurring after transfusion and alloimmunization: successful treatment with rituximab. Transfusion 2009;49:1370-4.
31. Alarif L, Castro O, Ofosu M, Dunston G, Scott RB. HLA-B35 is associated with red cell alloimmunization in sickle cell disease. Clin Immunol Immunopathol 1986;38:178-83.
32. Tormey CA, Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood 2009;114:4279-82.
33. Giblett ER. Testing, testing. Arch Intern Med 1978;138:469.
34. Giblett ER. Blood group alloantibodies: an assessment of some laboratory practices. Transfusion 1977;17:299-308.
35. Mohn JF, Lambert RM, Bowman HS, Brason FW. Experimental transfusion of donor plasma containing bloodgroup antibodies into incompatible normal human recipients. I. Absence of destruction of red cell mass with anti-Rh, anti-Kell and anti-M. Br J Haematol 1961;7:112-29.
36. Bowman HS, Brason FW, Mohn JF, Lambert RM. Experimental transfusion of donor plasma containing blood group antibodies into incompatible normal human recipients. II. Induction of isoimmune haemolytic anemia by a transfusion of plasma containing exceptional anti-CD antibodies. Br J Haematol 1961;7:130-45.
37. Gottschall JL, Triulzi DJ, Curtis B, et al. The frequency and specificity of human neutrophil antigen antibodies in a blood donor population. Transfusion 2011;51:820-7.
38. Payne R. The development and persistence of leukoagglutinins in parous women. Blood 1962;19:411-24.
39. Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization in female apheresis donors. Transfusion 1999;39:103-6.
40. [No authors listed]. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997;337:1861-9.
41. Endoh T, Kobayashi D, Tsuji N, et al. Optimal prewarming conditions for Rh antibody testing. Transfusion 2006;46: 1521-5.
42. Yamanishi H, Iyama S, Yamaguchi Y, Yanagihara T. The effect of reaction temperature for nephelometric assays for rheumatoid factor. Clin Chim Acta 2000;292:117-25.
43. Kaufman R. A fresh take on whole blood. Transfusion 2011; 51:230-3.
44. Campbell-Lee SA. The future of red cell alloimmunization. Transfusion 2007;47:1959-60.